

Natural Product Disaccharide Engineering through Tandem Glycosyltransferase Catalysis Reversibility and Neoglycosylation


Pauline Peltier-Pain,[†] Karen Marchillo,[‡] Maoquan Zhou,[†] David R. Andes,[‡] and Jon S. Thorson^{*,§}

Pharmaceutical Sciences Division, School of Pharmacy, Wisconsin Center for Natural Products Research, University of Wisconsin—Madison, 777 Highland Avenue, Madison, Wisconsin 53705-2222, United States, Department of Medicine and Medical Microbiology and Immunology, University of Wisconsin—Madison, 1685 Highland Avenue, Madison, Wisconsin 53705-2281, United States, and Center for Pharmaceutical Research and Innovation, University of Kentucky College of Pharmacy, 789 South Limestone Street, Lexington, Kentucky 40536-0596, United States

jsthorson@uky.edu

Received August 21, 2012

ABSTRACT



A two-step strategy for disaccharide modulation using vancomycin as a model is reported. The strategy relies upon a glycosyltransferase-catalyzed ‘reverse’ reaction to enable the facile attachment of an alkoxyamine-bearing sugar to the vancomycin core. Neoglycosylation of the corresponding aglycon led to a novel set of vancomycin 1,6-disaccharide variants. While the *in vitro* antibacterial properties of corresponding vancomycin 1,6-disaccharide analogs were equipotent to the parent antibiotic, the chemoenzymatic method presented is expected to be broadly applicable.

Leloir (sugar nucleotide-dependent) glycosyltransferases (GTs) are ubiquitous in nature where they serve to catalyze the transfer of monosaccharides to a wide array of acceptors including nucleic acids, polysaccharides, proteins, lipids, carbohydrates, and medicinally relevant secondary metabolites (Figure 1A).¹ A growing appreciation for the reversibility of GT-catalyzed reactions (Figure 1B)

has led to new GT-catalyzed methods for the exchange of sugars appended to complex natural-product scaffolds.² Building upon this concept, we recently reported that simple synthetic aromatic glycosides could serve as efficient donors in such reactions by dramatically altering the overall equilibrium in favor of sugar nucleotide formation (*i.e.*, the ‘reverse’ of a conventional GT-catalyzed reaction).³

[†] School of Pharmacy, Wisconsin Center for Natural Products Research, University of Wisconsin—Madison.

[‡] Department of Medicine and Medical Microbiology and Immunology, University of Wisconsin—Madison.

[§] University of Kentucky College of Pharmacy.

(1) (a) Gantt, R. W.; Peltier-Pain, P.; Thorson, J. S. *Nat. Prod. Reports* **2011**, *28*, 1811. (b) Chang, A.; Singh, S.; Phillips, G. N., Jr.; Thorson, J. S. *Curr. Opin. Biotechnol.* **2011**, *22*, 800. (c) Palcic, M. *Curr. Opin. Chem. Biol.* **2011**, *15*, 226. (d) Lairson, L.; Henrissat, B.; Davies, G. J.; Withers, S. G. *Annu. Rev. Biochem.* **2008**, *77*, 521. (e) Erb, A.; Weiss, H.; Harle, J.; Bechthold, A. *Phytochemistry* **2009**, *70*, 1812.

(2) (a) Zhang, C.; Griffith, B. R.; Fu, Q.; Albermann, C.; Fu, X.; Lee, I.-K.; Li, L.; Thorson, J. S. *Science* **2006**, *313*, 1291. (b) Modolo, L. V.; Escamilla-Treviño, L. L.; Dixon, R. A.; Wang, X. *FEBS Lett.* **2009**, *583*, 2131. (c) Zhang, C.; Moretti, R.; Jiang, J.; Thorson, J. S. *ChemBioChem* **2008**, *9*, 2506. (d) Minami, A.; Kakinuma, K.; Eguchi, T. *Tetrahedron Lett.* **2005**, *46*, 6187. (e) Zhang, C.; Albermann, C.; Fu, X.; Thorson, J. S. *J. Am. Chem. Soc.* **2006**, *128*, 16420. (f) Lairson, L. L.; Wakarchuk, W. W.; Withers, S. G. *Chem. Commun.* **2007**, 365. (g) Loughheed, B.; Ly, H. D.; Wakarchuk, W. W.; Withers, S. G. *J. Biol. Chem.* **1999**, *274*, 37717.

(3) Gantt, R. W.; Peltier-Pain, P.; Cournoyer, W. J.; Thorson, J. S. *Nat. Chem. Biol.* **2011**, *7*, 685.




Figure 1. (A) Classical GT reaction in which glycoside formation is thermodynamically favored. (B) GT reaction where an appropriately ‘activated’ glycoside donor (Donor*) shifts the reaction thermodynamics to favor sugar nucleotide formation. (C) One-pot coupled dual-GT-catalyzed reaction which combines GT-driven (OleD) sugar nucleotide synthesis with a subsequent GT-catalyzed (GtfE) glycosylation reaction to ultimately accomplish transglycosylation from a synthetic aromatic glycoside to a targeted aglycon (in this case, the vancomycin aglycon 3).

This pilot study also revealed that GT-driven sugar nucleotide synthesis could be directly coupled to another GT-catalyzed reaction to ultimately afford a transglycosylation reaction from the synthetic glycoside donor to a complex target scaffold (Figure 1C). To extend the prior pilot study, herein we describe the synthesis of 2-chloro-4-nitrophenyl 6'-deoxy-6'-methoxyamino- β -D-glucopyranoside and its application as a novel donor for (i) direct NDP-6'-deoxy-6'-methoxyamino-D-glucose synthesis and (ii) in situ dual-GT-catalyzed attachment of 6'-deoxy-6'-methoxyamino-D-glucose to the vancomycin aglycon for subsequent chemoselective neoglycosylation through a selective reaction

between a free reducing sugar and the alkoxyamine handle.⁴ Cumulatively, this model study illustrates a new general platform to generate disaccharide analogs of complex natural products with anticipated broad applicability.

The activated alkoxyaminosugar donor **1** for this study was synthesized in eight steps with an overall yield of 46% (see Supporting Information and Figure S1). Donor **1** was subsequently assessed as a substrate for the GT-catalyzed production of **2** in the presence of UDP and the enhanced GT (OleD TDP16) (see Figure S2).⁵ This reaction was conducted with a 1:1 ratio of glycoside donor to UDP and, after HPLC purification, provided 68 mg (88% isolated yield) of the desired product (**2**) (see Supporting Information for full characterization). This illustrated efficiency of the OleD TDP16-catalyzed reverse reaction with the non-native donor **1** sugar sets the stage for a potential one-pot procedure for alkoxyaminosugar attachment to the model vancomycin aglycon as described below and also provides a facile route to a potentially new reagent for glycobiology.

(4) (a) Peri, F.; Dumy, P.; Mutter, M. *Tetrahedron* **1998**, *54*, 12269. (b) Peri, F.; Deutman, A.; La Ferla, B.; Nicotra, F. *Chem. Commun.* **2002**, 1504. (c) Peri, F.; Jimenez-Barbero, J.; Garcia-Aparicio, V.; Tvaroska, I.; Nicotra, F. *Chem.—Eur. J.* **2004**, *10*, 1433. (d) Griffith, B. R.; Langenhan, J. M.; Thorson, J. S. *Curr. Opin. Biotechnol.* **2005**, *16*, 622. (e) Langenhan, J. M.; Peters, N. R.; Guzei, I. A.; Hoffman, F. M.; Thorson, J. S. *Proc. Natl. Acad. Sci. U.S.A.* **2005**, *102*, 12305. (f) Griffith, B. R.; Krepel, C.; Fu, X.; Blanchard, S.; Ahmed, A.; Edmiston, C. E.; Thorson, J. S. *J. Am. Chem. Soc.* **2007**, *129*, 8150. (g) Ahmed, A.; Peters, N. R.; Fitzgerald, M. K.; Watson, J. A., Jr.; Hoffman, F. M.; Thorson, J. S. *J. Am. Chem. Soc.* **2006**, *128*, 14224. (h) Goff, R. D.; Thorson, J. S. *J. Med. Chem.* **2010**, *53*, 8129. (i) Goff, R. D.; Thorson, J. S. *Chem. Med. Chem.* **2011**, *6*, 7774. (j) Langenhan, J. M.; Engle, J. M.; Slevin, L. K.; Fay, L. R.; Lucker, R. W.; Smith, K. R.; Endo, M. M. *Bioorg. Med. Chem. Lett.* **2008**, *18*, 670. (k) Peltier-Pain, P.; Timmons, S. C.; Grandemange, A.; Benoit, E.; Thorson, J. S. *Chem. Med. Chem.* **2011**, *6*, 1347. (l) Goff, R. D.; Thorson, J. S. *Org. Lett.* **2009**, *11*, 461. (m) Goff, R. D.; Thorson, J. S. *Org. Lett.* **2012**, *14*, 2454.

(5) Williams, G. J.; Yang, J.; Zhang, C.; Thorson, J. S. *ACS Chem. Biol.* **2011**, *6*, 95.

(6) (a) Khane, D.; Leimkuhler, C.; Lu, W.; Walsh, C. T. *Chem. Rev.* **2005**, *105*, 425. (b) Butler, M. S.; Cooper, M. A. *J. Antibiot.* **2011**, *64*, 413. (c) Butler, M. S. *Nat. Prod. Report* **2008**, *25*, 475. (d) Mishra, B. B.; Tiwari, V. K. *Eur. J. Med. Chem.* **2008**, *46*, 4769.

The complex natural product model selected for this study (the glycopeptide vancomycin) is a treatment of last resort for certain antibiotic-resistant Gram-positive pathogens.⁶ The selection for this model was based upon the known impact of sugar modification upon improving the activity of vancomycin analogs against vancomycin-resistance bacteria,^{4f,7} and the permissive nature of the vancomycin GT GtFE.⁸ Vancomycin aglycon (**3**) was readily obtained by acid hydrolysis of vancomycin,^{4f,9} and, with the simple activated 2-chloro-4-nitrophenyl glycoside (**1**) in hand, we attempted to form the monoglycosylated vancomycin derivative (**4**) using a dual-GT-catalyzed coupled reaction (Figure 1C). The optimized single-pot reaction (50 mM Tris-HCl buffer, pH 8.5; 1.2 mM donor **1**; 1 mM UDP; 1 mM vancomycin aglycon **3**; 4 μ M OleD TDP16; 10 μ M GtFE; 30 °C) was followed by analytical HPLC (see Figure S5). Notably, conversion to the desired product (**4**) in this one-pot reaction (47%) was comparable to the GtFE-catalyzed production of **4** directly from UDP-Glc and **3** (53%).³ To generate sufficient material for downstream neoglycosylation, the dual-GT-catalyzed reaction was scaled (200 mL reaction volume) which, after deprotection and simple purification, afforded 150 mg of the desired product **4** (35% isolated yield; see Supporting Information for full characterization) for subsequent neoglycosylation using representative sugars found within the bacterial cell wall or appended to glycopeptides.

A wide variety of uniquely functionalized carbohydrates decorate the peptide backbone of naturally occurring glycopeptides and other antibiotics. Most of these sugars fall within the hexo- and 6-deoxyhexopyranosides and include D-glucose, L-rhamnose, L-vancosamine, D-glucosamine, and the 2'-N-acyl-D-glucolipid found in teicoplanin (**6**).¹⁰ In addition to these four sugars represented among glycopeptides, we also selected the highly deoxygenated D-forosamine from the macrolide spiramycin (**7**) and insecticidal spinosyns (**8**) (Figure 2),¹¹ and N-acetyl-muramic




Figure 2. Structures of the natural glycopeptide antibiotics vancomycin (**5**) and teicoplanin (**6**) and known natural products containing D-forosamine.

acid, a main component of bacterial peptidoglycan. Among this series, D-glucose, L-rhamnose, D-glucosamine, and N-acetyl-muramic acid were commercially available, a representative 2'-N-acyl-D-glucolipid was synthesized as previously described,^{4f} and D-forosamine and L-vancosamine were generated via acid hydrolysis of spiramycin and alloc-protected vancomycin, respectively.⁹ For the pilot reaction, compound **4** was dissolved in DMSO/AcOH, followed by the addition of a 10-fold excess of D-glucose. The reaction was




Figure 3. Neoglycosylation of the 6'-alkoxyaminosugar-substituted vancomycin neoglycon (**4**) (upper). The products of the neoglycosylation reaction with corresponding conversions based upon HPLC are illustrated (lower). Full characterization of **9–16** is presented in the Supporting Information.

(7) (a) Ge, M.; Chen, Z.; Onishi, H. R.; Kohler, J.; Silver, L. L.; Kerns, R.; Fukuzawa, S.; Thompson, C.; Khane, D. *Science* **1999**, *284*, 507. (b) Jabès, D.; Candiani, C.; Romano, G.; Brunati, C.; Riva, M.; Cavaleri, M. *Antimicrob. Agents Chemother.* **2004**, *48*, 1118. (c) Patti, G. J.; Kim, S. J.; Yu, T.-Y.; Dietrich, E.; Tanaka, K. S. E.; Parr, T. R., Jr.; Rafai Far, A.; Schaefer, J. *J. Biol. Chem.* **2009**, *392*, 1178. (d) Ritter, T. K.; Mong, K.-K. T.; Liu, H.; Nakatani, T.; Wong, C.-H. *Angew. Chem., Int. Ed.* **2003**, *42*, 4657. (e) Liu, Y.-C.; Li, Y.-S.; Lyu, S.-Y.; Hsu, L.-J.; Chen, Y.-H.; Huang, Y.-T.; Chan, H.-C.; Huang, C.-J.; Chen, G.-H.; Chou, C.-C.; Tsai, M.-D.; Li, T.-L. *Nat. Chem. Biol.* **2011**, *7*, 304. (f) Oh, T.-J.; Kim, D. H.; Kang, S. Y.; Yamaguchi, T.; Sohng, J. K. *J. Antibiot.* **2011**, *64*, 103.

(8) (a) Fu, X.; Albermann, C.; Zhang, C.; Thorson, J. S. *Org. Lett.* **2005**, *7*, 1513. (b) Losey, H. C.; Jiang, J.; Biggins, J. B.; Oberthür, M.; Ye, X.-Y.; Dong, S. D.; Kahne, D.; Thorson, J. S.; Walsh, C. *Chem. Biol.* **2002**, *9*, 1305. (c) Fu, X.; Albermann, C.; Jiang, J.; Lia, J.; Zhang, C.; Thorson, J. S. *Nat. Biotechnol.* **2003**, *21*, 1467. (d) Solenberg, P. J.; Matsushima, P.; Stack, D. R.; Wilkie, S. C.; Thompson, R. C.; Baltz, R. H. *Chem. Biol.* **1997**, *4*, 195.

(9) Thompson, C.; Ge, M.; Kahne, D. *J. Am. Chem. Soc.* **1999**, *121*, 1237.

(10) Nicolaou, K. C.; Boddy, C. N. C.; Bräse, S.; Winssinger, N. *Angew. Chem., Int. Ed.* **1999**, *38*, 2096.

(11) (a) Nguyen, H. C.; Karray, F.; Lautru, S.; Gagnat, J.; Lebrihi, A.; Ho Huynh, T. D.; Pernodet, J.-L. *Antimicrob. Agents Chemother.* **2010**, *54*, 2830. (b) Waldron, C.; Matsushima, P.; Rosteck, P. R., Jr.; Broughton, M. C.; Turner, J.; Madduri, K.; Crawford, K. P.; Merlo, D. J.; Baltz, R. H. *Chem. Biol.* **2001**, *8*, 487.

allowed to proceed at 40 °C and monitored by HPLC. Within 16 h, the starting material was fully consumed, and the newly generated material (**9**) was subsequently isolated by preparative HPLC (Figure 3). Neoglycosides **10** to **16** were generated in identical fashion (isolated yields from 31 to 95%; see Supporting Information for full characterization), and with the exception of compound **10**, which was formed as an α/β (1:2) mixture, exclusive formation of a single anomer was observed. HMBC and ROESY experiments revealed a strong correlation between the anomeric proton of the neoglycoside with C-6 and H-6 of the alkoxyaminosugar respectively, supporting the regioselectivity of attachment (see Figure S8).

Neoglycosides **9**–**16** and aglycon **3** were found to inhibit growth of two methicillin-resistant (33491 and MW2) bacteria at a concentration between 0.25 to 16 $\mu\text{g/mL}$ (MIC of vancomycin **5** = 0.5 and 0.25 $\mu\text{g/mL}$ respectively), whereas no significant growth inhibition of vancomycin-resistant strains (Van A 256, VA-21) by **9**–**16** was observed (MIC = 64 $\mu\text{g/mL}$) (see Table S3). Thus, while the current range of analogs were unable to circumvent resistance mechanisms, this analysis suggests that 1,6-neoglycosyl

modification does not infringe upon the standard vancomycin mechanism of action. More importantly, this model study illustrates an enabling platform for the disaccharide modification of complex biomolecules for which permissive glycosyltransferases are available.¹²

Acknowledgment. We thank the School of Pharmacy Analytical Instrumentation Center (University of Wisconsin—Madison) for analytical support. This work was supported by funding from the NIH (AI52218).

Note Added after ASAP Publication. Maoquan Zhou was changed to full authorship and removed from the Acknowledgment, this paper published ASAP on September 17, 2012 and reposted with this change on September 21, 2012.

Supporting Information Available. Materials and methods, synthetic procedures, and products characterizations. This material is available free of charge via the Internet at <http://pubs.acs.org>.

(12) Williams, G. J.; Thorson, J. S. *Adv. Enzymol. Relat. Areas Mol. Biol.* **2009**, *76*, 55.

The authors declare the following competing financial interest(s): J.S.T. is a co-founder of Centrose (Madison, WI).